Several series of compounds (benzoic acids, pyrazolecarboxylic acids, phenoxyacetic acids, and quinolinoxyacetic acids) were prepared and evaluated for their inhibitory activity against PTP-1B. Several compounds showed submicromolar inhibitory activity.
Introduction
Protein tyrosine phosphatase 1B (PTP-1B) plays a crucial role in the modulation of insulin signaling pathway through dephosphorylation of the activated insulin receptor.
1 Since Echelby and coworkers 2 reported that PTP-1B knock-out mice showed improved insulin sensitivity and resistance to weight gain, PTP-1B has emerged as an attractive therapeutic target for treatment of insulin resistance related to Type 2 diabetes. 3 Thus, PTP-1B inhibitors could potentially ameliorate insulin resistance and normalize plasma glucose and insulin without inducing hypoglycemia. 4 Recently, small molecule inhibitors of PTP-1B as well as peptide mimetics were reported in literatures. 5 They included oxalamides (1, 2), benzoic acid (3), and phenoxyacetic acids (4-7) (Figure 1 ). 4 One of the inhibitors, Ertiprotafib (7) went to clinical trial, but was discontinued in Phase II due to insufficient efficacy and dose-dependent side effects. In the preceding papers from this laboratory, the 1,2-naphthoquinone and catechol derivatives were reported as new classes of PTP-1B inhibitors. PTP-1B, esters 10 were found to be inactive. Similar trend was also observed in the result of HTS. Pyrazole derivative with octyl group 11a showed moderate activity while the tetradecyl derivative 11b showed superior activity. Further study was not pursued due to consideration of patentability.
Then the attention was moved to derivatives of isoxazoles and fused isoxazoles. First, isoxazolylphenoxy acids were prepared as shown in Scheme 2 and tested toward PTP-1B to study the effect of structural modifications to the inhibitory activity. The phenoxyacetic acid moiety was incorporated as some of the o-quinones substituted with phenoxyacetic acid showed micromolar inhibitory activity in the earlier paper, 6a and also many phenoxyacetic acid derivatives including Ertiprotafib 7 have been reported as PTP-1B inhibitors. Various derivatives were easily obtained by 1,3-dipolar cycloaddition of nitriles, alkynes, and indoles with chlorooxime 12 to give oxadiazolyl derivatives 14, isoxazolyl derivatives 16, and dihydroisoxazolo [5,4-b] indole derivatives 18, respectively.
When tested for enzyme inhibitory activity against PTP-1B, only the parent isoxazole (16a) with decyl chain showed moderate inhibitory activity. Either oxadiazolyl derivatives 14 or dihydroisoxazolo [5,4-b] indole derivatives 18 were not effective inhibitors of PTP-1B.
The second attempt in the modification of the isoxazole series was preparation of benzoisoxazole derivatives. 4-(Benzoisoxazol-3-yl)benzoic acid derivatives were prepared as shown in Scheme 3. Hydroxybenzophenone 19 was prepared by palladium-catalyzed coupling of salicylaldehyde with aryl iodide. 7 Benzoisoxazolyl benzoate 20 was prepared by cyclocondensation of 2-hydroxybenzophenone 19. 8 The derivatives 23, 24, 26, and 27 were prepared from 20 with introduction of various substituents at 5-position of benzoisoxazole ring by palladium-mediated introduction of aryl and alkenyl groups. 9 Aromatic derivatives, 23 and 24 did not show any significant activities, whereas alkyl derivatives 26a and 27 showed improved activity compared to parent 21. But tetradecyl derivative 26b showed submicromolar activity. Thus introduction of aromatics to the aromatic ring of 1,2-benzoisoxazoles was detrimental to the inhibitory activity, while introduction of hydrocarbon chains to the aromatics increased the inhibitory activity significantly. Similar trend was also observed in the other series.
Then quinoline derivatives were prepared because isosteres of quinoline were also discovered as hits from HTS. Alkyl groups were introduced by palladium-mediated reaction of 3-iodoquinolines, 10 which was in turn prepared by chlorination of 4-hydroxy-3-iodoquinolines. The aryloxyacetic acid was introduced by alkylation of phenolic group with bromoacetates and subsequent hydrolysis.
While 3-phenyl derivative 42 and dicarboxylic acid 47 did not show activity, octyl derivatives 31, 39, and 44 (42 with insertion of benzene) showed moderate activities. Octenyl derivative with 8-acetoxy group 37 (unsaturated form of 39) showed improved activity with an IC 50 of 3.27 µM. Tetracedyl derivative 34 and 6-octyloxyquinoline-3-carboxylic aicd 50 showed submicromolar activities. Thus the positive action of alkyl substitution also worked in this quinoline series.
The selectivity of the inhibitors is important to minimize the undesirable side effects of a drug. Thus the selectivity of the selected inhibitors was tested likewise against nine phosphatases using the same concentration of FDP as substrate and the result is shown in Table 2 . The isozyme selectivities are generally good except against YOP and cdc25B.
Experimental Section

1-(4-Octylbenzyl)pyrazole-3-carboxylic acid (11a).
A mixture of 1H-pyrazole-3-carboxylic acid ethyl ester 8 (1.00 g, 7.1 mmol), 4-bromobenzyl bromide (2.14 g, 8.6 mmol), patassium hydroxide (600 mg, 10.7 mmol) in THF (40 mL) was heated for 12 h at reflux and partitioned between brine and ethyl acetate. The organic layer was dried with MgSO4, filtered, and concentrated. The residue was purified by column chromatography to give 1-(4-bromobenzyl)-1H-pyrazole-3-carboxylic acid ethyl ester 9 (1.7 g, 81%) as white solid: A mixture of (4-chlorocarbooxiimidoylphenoxy)acetic acid ethyl ester 12 (1.3 g, 6.0 mmol) and 4-bromobenzonitrile (3.2 g, 31 mmol) in toluene (20 mL) was stirred for 2 h at room temperature, and poured into water (10 mL). The resulting mixture was extracted with ethyl acetate and the organic layer was dried with MgSO4 and concentrated in vacuo. The residue was purified by column chromatography to give {4- [5-(4- [4-(5-Decylisoxazol-3-yl)phenoxy]acetic acid (16a). A mixture of 12 (1.57 g, 7.00 mmol), 1-dodecyne (4.1 mL, 12.8 mmol) and triethylamine (0.90 mL, 12 mmol) in ether (30 mL) was stirred for 5 h at room temperature, and poured into water (15 mL). The resulting mixture was extracted with 40 mL of ethyl acetate and the organic layer was dried with MgSO 4 
4-(5-Bromobenzo[d]isoxazol-3-yl)benzoic acid ethyl ester (20).
A mixture of 5-bromo-2-hydroxybenzaldehyde (10 g, 51 mmol), ethyl 4-iodobenzoate (16 g, 56 mmol), LiCl (475 mg, 11.2 mmol), PdCl 2 (500 mg, 2.8 mmol), Na 2 CO 3 (11.9 g, 112 mmol) and DMF in a pressure tube was heated at 100 o C for 12 h to afford ethyl 4-(5-bromo-2-hydroxybenzoyl)benzoate 19 (6.0 g, 32%) as a yellow oil. A mixture of the above ester, NH 2 OH·HCl, and NaOAc in ethanol was heated for a day and partitioned between ethyl acetate and water. The organic layer was washed with water, dried with MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography to afford the oxime (4.4 g, 67%). The oxime was heated in acetic anhydride for 30 min until dissolved and extracted with ethyl acetate. The organic layer was dried with MgSO 4 , and concentrated in vacuo to give oxime acetate (5.3 g, 92%). The oxime acetate and Na 2 CO 3 (2.7 g, 26 mmol) in tri(ethyleneglycol) dimethyl ether was heated for 30 min at 230 o C and the solvent was removed by vacumn distillation. The residue was partitioned between ethyl acetate and water. The organic layer was dried with MgSO4, and concentrated in vacuo and the residue was purified by column chromatography to afford 20 (2.7 g, 65%): 
4-(5-Bromobenzo[d]isoxazol-3-yl)benzoic acid (21).
A mixture of 20 (34.6 mg, 0.1 mmol) and several drops of dilute sodium hydroxide solution in MeOH (5 mL) was stirred for 2 h at room temperature and acidified by addition of dilute hydrochloric acid. After extraction with ethyl acetate, the organic layer was washed with water, dried with MgSO4, and concentrated in vacuo to give 29 mg (91%) of 21 as white crystals: 
4-(5-Tetradecylbenzo[d]isoxazol-3-yl)benzoic acid (26b).
A DMF (5 mL) solution of 20 (110 mg, 0.317 mmol), 1-tetradecene (148 mg, 0.76 mmol), NaHCO3 (65 mg, 0.76 mmol), (n-Bu)4NCl (90 mg, 0.317 mmol), and Pd(OAc)2 (3.6 mg, 5 mol%) in a pressure bottle filled with nitrogen was heated for 12 h. The resulting mixture was partitioned between saturated NH 4 in vitro Enzyme Assay. The tests were performed against recombinant human PTP-1B using fluorescein diphosphate (FDP) as a substrate. The medium was 30 mM Tris, 75 mM NaCl, 0.67 mM EDTA in 1 mM DTT (pH 8.0) buffer with 20 µM FDP, and 0.1 µg of PTP-1B. After an hour at room temperature with inhibitor, the enzyme activity was determined by measuring the fluorescence of the product, fluorescein monophosphate (FMT) at 485 nm (excitation) and 538 nm (emission). IC 50 (µM) values were determined from direct regression curve analysis. Isozyme selectivity was determined likewise using appropriate phosphatases.
Conclusion
Several classes of compounds (heteroarylcarboxylic acids, phenoxyacetic acids, and quinolinoxyacetic acids) were prepared and tested as PTP-1B inhibitors. Some of the compounds showed remarkable inhibition in in vitro assays. Compounds with long chain alkyl substituents showed submicromolar IC 50 , suggesting that the inhibition can be enhanced by lipophilic substitution within these classes of compounds.
